Ongoing Clinical Trials for Inner Ear Disorder
This article provides information about ongoing clinical trials for inner ear disorder. Currently, there is 1 clinical trial exploring treatment options for patients with this condition. The trial is investigating the use of methylprednisolone to reduce vertigo attacks in patients with Menière’s disease, a disorder affecting the inner ear.
Clinical trial locations
Study on Meniere’s Disease: Comparing Methylprednisolone and Placebo for Patients with Unilateral Meniere’s Disease
This clinical trial is being conducted in the Netherlands and focuses on Menière’s disease, a condition affecting the inner ear that causes episodes of vertigo, which is a sensation of spinning or dizziness. The study is investigating whether methylprednisolone, a corticosteroid medication, can help reduce the frequency of vertigo attacks more effectively than a placebo.
Main inclusion criteria:
- Must be diagnosed with unilateral Menière’s disease, meaning the condition affects only one ear
- Must be over 18 years old
- Must have experienced at least 4 vertigo attacks in the last 6 months
- Both males and females can participate
Main exclusion criteria:
- Patients without a diagnosis of unilateral Menière’s disease cannot participate
- Those who are part of vulnerable populations, such as children or pregnant women
- Patients with other medical conditions that might interfere with the study
- Those currently participating in another clinical trial
- Patients with allergies or adverse reactions to the study medication
- Those who have had recent surgery or medical procedures that might affect the study
- Patients unable to follow study procedures or attend follow-up visits
Focus and goal: The trial aims to determine whether intratympanic injections of methylprednisolone are more effective than a placebo in reducing vertigo attacks in patients with Menière’s disease. The treatment is delivered through injections directly into the ear, allowing the medication to target the affected area more effectively. The study will monitor participants over one year and assess not only the frequency of vertigo attacks but also quality of life aspects related to dizziness and tinnitus. The trial will also evaluate the use of other medications such as dexamethasone, triamcinolone, and gentamicin, along with metoclopramide for managing nausea and vomiting during vertigo attacks.
Investigational drug: Methylprednisolone is a corticosteroid medication used to reduce inflammation and suppress the immune response. In this trial, it is administered at a dosage of 62.5 mg/ml through intratympanic injections directly into the middle ear. The medication works by reducing inflammation in the inner ear, which can help decrease the frequency of vertigo episodes. By targeting the affected area directly, this method of delivery is intended to provide more effective relief from symptoms.
Throughout the trial, participants will undergo regular monitoring and follow-up assessments to evaluate the treatment’s effectiveness and safety. They may be asked to complete questionnaires about their quality of life and any changes in their symptoms.
Summary
Currently, there is one active clinical trial available for patients with inner ear disorder, specifically focusing on Menière’s disease. This trial is taking place in the Netherlands and is investigating the effectiveness of methylprednisolone injections compared to placebo in reducing vertigo attacks. The study represents an important effort to find better treatment options for patients experiencing this debilitating condition, which can significantly impact daily life due to unpredictable episodes of vertigo, hearing loss, and associated symptoms. The trial is open to adults over 18 who have been diagnosed with unilateral Menière’s disease and have experienced frequent vertigo attacks in recent months.